EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann–Sträussler–Scheinker disease mutation

Andrew Fang, Xinli Tang, Madeleine Fleming, Brian Tancowny, Xiongyao Wang, YongLiang Wang, Nathalie Daude, Lyudmyla Dorosh, Shelaine C Fleck, Vineet Rathod, Virginie Coustou, Silvia A Cervantes und 9 weitere

Acta Neuropathologica · 2026

DOI: 10.1007/s00401-026-03015-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2026. Verfasst von Andrew Fang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Alberta, Edmonton, AB, T6G 2R3, Canada. Hauptthemen laut MEDLINE: Gerstmann-Straussler-Scheinker Disease, Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Prion Research Institute, Canada Foundation for Innovation, Alberta Environment and Protected Areas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prion diseases are transmissible, fatal, neurodegenerative disorders driven by the conformational misfolding of the cellular prion protein (PrP C ) into an infectious, aggregation-prone conformer (PrP Sc ). While the accumulation of PrP Sc represents the central pathogenic event, targeting it directly and specifically has proven difficult due to its structural heterogeneity and similarity to PrP C . Consequently, previous immunization efforts have largely focused on PrP C , though with limited success. Here, we employed a model-based approach to design a vaccine that specifically mimics immunogenic features hypothesized to be present on the surface of PrP Sc . By mimicking predicted surface residues and using an innocuous, cross-beta fibril scaffold derived from the fungal protein HET-s (218–289), we were able to generate unique, conformation-dependent epitopes not found on PrP C . We evaluated our vaccine by immunizing a genetic prion disease mouse model of Gerstmann–Sträussler–Scheinker disease, a genetic prion disorder. Vaccination was able to significantly delay the onset of disease in immunized mice (412 ± 88 days) compared to unimmunized (177 ± 17 days) and scaffold-immunized (161 ± 27 days) animals, and supplementation with adjuvants including Freund’s adjuvant (448 ± 39 days), QS-21 (479 ± 58 days), and Alum (506 ± 52 days) was able to further enhance the vaccine efficacy. To investigate the mechanism of neuroprotection, we derived a monoclonal antibody from a vaccinated mouse and mapped its discontinuous, conformation-specific epitope, comprising an aspartate–histidine pair that may be occluded in PrP C , and confirmed the antibody’s ability to differentiate between infectious and uninfected prion samples. Our study demonstrates the feasibility of a model-based approach for prion vaccine design and targeting of the infectious prion protein, providing groundwork for future development of not only potential prion therapeutic interventions, but also targeting related neurodegenerative disorders characterized by protein misfolding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gerstmann-Straussler-Scheinker DiseaseVaccinesAnimalsMice, TransgenicMiceDisease Models, AnimalMutationPrPSc Proteins

Stichwörter der Autor:innen

Epitope predictionGSSMolecular modelingPrion vaccineProtein engineeringStructure-based vaccine

Substanzen

VaccinesPrPSc Proteins

Autor:innen und Institutionen

  • Department of Biochemistry, University of Alberta, Edmonton, AB, T6G 2R3, Canada.
  • Centre for Prions and Protein Folding Diseases, University of Alberta, 110C Brain and Aging Research Building (BARB), Edmonton, AB, T6G 2M8, Canada.
  • School of Materials Science and Engineering, Harbin Institute of Technology, Weihai, Shandong, China.
  • Department of Cell Biology and Anatomy, University of Calgary, Calgary, AB, T2N 1N4, Canada.
  • Department of Electrical & Computer Engineering, University of Alberta, Edmonton, AB, T6G 1H9, Canada.
  • Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, AB, T1K 3M4, Canada.

Förderung

  • Alberta Prion Research Institute
  • Canada Foundation for Innovation
  • Alberta Environment and Protected Areas
  • Natural Sciences and Engineering Research Council of Canada
  • NIH HHS
  • Alberta Conservation Association
  • Alberta Innovates
  • Creutzfeldt-Jakob Disease Foundation

Zitieren

APA

Fang, A., Tang, X., Fleming, M., Tancowny, B., Wang, X., Wang, Y., Daude, N., Dorosh, L., Fleck, S. C., Rathod, V., Coustou, V., Cervantes, S. A., Velásquez, C. D., Westaway, D., Aiken, J., McKenzie, D., Telling, G., Stepanova, M., Saupe, S. J., …, & Wille, H. (2026). A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann–Sträussler–Scheinker disease mutation. Acta Neuropathologica. https://doi.org/10.1007/s00401-026-03015-4

Vancouver

Fang A, Tang X, Fleming M, Tancowny B, Wang X, Wang Y, et al. A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann–Sträussler–Scheinker disease mutation. Acta Neuropathologica. 2026. doi:10.1007/s00401-026-03015-4

BibTeX
@article{Fang2026,
  author = {Fang, Andrew and Tang, Xinli and Fleming, Madeleine and Tancowny, Brian and Wang, Xiongyao and Wang, YongLiang and Daude, Nathalie and Dorosh, Lyudmyla and Fleck, Shelaine C and Rathod, Vineet and Coustou, Virginie and Cervantes, Silvia A and Velásquez, Camilo Duque and Westaway, David and Aiken, Judd and McKenzie, Debbie and Telling, Glenn and Stepanova, Maria and Saupe, Sven J and Siemer, Ansgar B and Wille, Holger},
  title = {A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann–Sträussler–Scheinker disease mutation},
  journal = {Acta Neuropathologica},
  year = {2026},
  doi = {10.1007/s00401-026-03015-4}
}
Kostenlos starten →